Market Opportunity and Unmet Needs - Achieve Life Sciences has a unique opportunity to address a market of up to 50 million Americans who use tobacco with Cytisinicline[6] - Nicotine dependence is a public health crisis costing billions of dollars[6] and there are ~29 million US smokers with few treatment options[12] - Approximately 60% of adult e-cigarette users want to quit[14], with ~17 million US adults reporting e-cigarette use[16] - An estimated $11 Billion Rx opportunity exists in the market[46] Cytisinicline's Potential and Clinical Data - Cytisinicline is presented as the first potential new nicotine dependence treatment option in nearly 20 years[6, 18] - ORCA-2 and ORCA-3 trials showed strong results in smoking cessation, demonstrating efficacy, tolerability, and craving reduction[22] - In the 12-week Cytisinicline Treatment, the quit rate is 32.6% compared to 7% in the placebo group[23] - In the 6-week Cytisinicline Treatment, the quit rate is 25.3% compared to 4.4% in the placebo group[23] - Phase 2 ORCA-V1 trial showed a 2.6x (p=0.035) increased likelihood of quitting vaping with cytisinicline[39] Commercialization Strategy - The company anticipates filing a Smoking cessation NDA with launch expected in 2H26[6] - A focused launch strategy will leverage innovative, data-driven solutions to drive adoption and future growth[7] - The company will focus on high-volume prescribers and engaged quitters[48] - The company will target the varenicline market share, which peaked at ~2.8M Rx (75% in U S market - $800M)[51]

For personal use only 2025 AUSTRALIAN RICE CONFERENCE Shaping the future Paul Serra SunRice Group CEO August 2025 2 0 2 5 A U S T R A L I A N R I C E C O N F E R E N C E Important notice & disclaimer This presentation has been prepared by Ricegrowers Limited (SunRice) and provides summary information only. SunRice has prepared this presentation in good faith believing the statements made in it to be true as at the date of the presentation. SunRice is not otherwise warranting the accuracy of the information ...

For personal use only Bioshares Annual Conference Q&A presentation Hobart August 7, 2025 ® Xanamem is a registered trademark of Actinogen Medical Limited Disclaimer For personal use only Bioshares Q&A August 7, 2025 2 • This presentation has been prepared by Actinogen Medical Limited. ("Actinogen" or the "Company") based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make a ...

Commercialising Next -Generation Laser Enrichment Technology Equity Raising Presentation | August 2025 This Presentation has been prepared by Silex Systems Limited ABN 69 003 372 067 (Silex or Company) (ASX: SLX) (OTCQX: SILXY) and is dated 7 August 2025. The information contained in this Presentation is current as at the date of this Presentation or such earlier date as specified in this Presentation. This Presentation has been prepared in connection with the Company's proposed equity raising (Offer) of ne ...

Capital Raising Presentation 7 August 2025 NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES For personal use only ASX: LTR | ltresources.com.au NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES Important Information IMPORANT INFORMATION NOTICE AND DISCLAIMERS This investor presentation (Presentation) is dated 7 August 2025 and has been prepared by Liontown Resources Limited (ACN 118 153 825) (ASX: LTR) (Liontown or the Company). By accepting this Presentation, you represent and warrant that you are e ...

This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws, including any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management, including for future operati ...

Q2 2025 Financial Performance - Adjusted EPS reached $5.13, a 13% year-over-year increase, or 17% on a constant macro basis[10] - Revenues totaled $1.102 billion, up 13% year-over-year[10] - Adjusted EBITDA was $621 million, a 12% year-over-year increase[10] - The company reported organic revenue growth of 11%[10] - Revenue retention improved to 92.3%[10] Segment Performance - Corporate Payments revenue grew by 18%[10] - Vehicle Payments organic revenue growth was 9%[16] - Lodging Payments experienced a decline of 2%[16] - Other segments, including Gift and Payroll Cards, grew by 18%[16] Liquidity and Capital Allocation - Liquidity as of June 30, 2025, was approximately $3.5 billion[23] - Adjusted EBITDA was reported as $621 million[26] - Free cash flow generated was $366 million[26] - The company's leverage ratio was 2.53x[23] 2025 Guidance - The company projects second-half adjusted EPS to accelerate to $11.40, an 18% increase over the first half of 2025[32] - Organic revenue growth in the second half is expected to be 10%[32]

SunOpta Inc. Earnings Presentation Q2 2025 © SunOpta Inc. 2025 1 1 Q2 2025 General Disclosures This presentation contains forward-looking statements that reflect the Company's current views about future events and financial performance. These forward-looking statements are subject to important risks and uncertainties, as well as other factors and assumptions that could cause actual results to differ materially from those anticipated or implied in the statements. Certain non-GAAP financial measures are used ...

NYSE: DHX Q2 2025 Investor Presentation August 6, 2025 Forward looking statements This presentation and oral statements made from time to time by our representatives contain forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You should not place undue reliance on those statements because they are subject to numerous uncertainties and ...

Q2 2025 Performance Highlights - Lyft's active riders reached 261 million, a 10% year-over-year increase and an all-time high[7, 23, 24] - Total rides amounted to 2348 million, a 14% year-over-year increase and an all-time high[7, 26, 27] - Gross bookings reached $45 billion, a 12% year-over-year increase and an all-time high[7, 30] - Adjusted EBITDA reached $129 million, resulting in a 29% margin of gross bookings, marking an all-time high[7, 32, 33] - Free cash flow for the trailing twelve months was $993 million[7, 35, 37] Growth Strategy & Partnerships - Over 50 million rides were connected to a partnership in Q2'25, an increase of over 25% year-over-year[10] - Riders connected to a partner were 15x more likely to choose a high-value mode and took rides that are 13x longer, on average, during Q2[11] Q3 2025 Guidance - Gross bookings are projected to be approximately $465 billion to $480 billion, representing a 13% to 17% year-over-year increase[38] - Adjusted EBITDA is expected to be between $125 million and $145 million[38] - Adjusted EBITDA margin is anticipated to be approximately 27% to 30% of gross bookings[38] Financial Efficiency - Marketplace incentives continue to deliver leverage, with the company on track to deliver its 2024 to 2027 target of 10% annual incentive efficiencies[41]